Compare AGNC Investment Corp (AGNC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGNC Investment Corp vs BIO-TECHNE Corp — how do they compare? AGNC Investment Corp trades at $10.86 (market cap $12.74B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: AGNC Investment Corp and BIO-TECHNE Corp are close in size by market cap, and AGNC Investment Corp pays the higher dividend (13.4%). Which is the better fit depends on your goals.
| AGNC | TECH | |
|---|---|---|
Market Cap | $12.74B | $11.24B |
Sector | Financials | Health |
52-Week High | $12.17 | $72.29 |
52-Week Low | $9.33 | $43.31 |
Dividend Yield | 13.4% | 0.44% |
Enterprise Value | — | $11.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGNC Investment trades at $10.84, up 2.17% today, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The stock offers a high dividend yield, with consistent monthly payouts, and trades at a P/E of 5.39 and P/B of 1.22. Recent news highlights its 13%+ yield and stable dividend history, though analyst consensus is mixed with a Hold majority.
Outlook remains positive due to robust net income margins above 94% and economic returns, but risks include interest rate sensitivity and leveraged mortgage securities. The consensus price target of $11.30 suggests modest upside, supported by institutional interest and earnings momentum, though volatility from macroeconomic factors warrants caution.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AGNC Investment Corp
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
Read more on AGNC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
